Overview

Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action

Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to understand better the mechanisms of action of calcitonin gene related peptide (CGRP) targeted monoclonal antibodies in migraine prevention. Specifically, the protocol will allow the investigators to determine whether the main site of action of this novel and recently-approved class of migraine prophylactic drugs act inside or outside the brain and if so, where.
Phase:
Phase 4
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborator:
Eli Lilly and Company
Treatments:
Erenumab